Why Revolution Medicines May Be Big Pharma's Next Takeover Target

Revolution Medicines (NASDAQ:RVMD | RVMD Price Prediction) closed at $205.55 on August 11, 2026, giving the pre-commercial oncology platform a market cap of $44.1 billion.

24/7 Wall Street • Aug 12, 2026

BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration

SAN CARLOS, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, and Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced a multi-part collaboration including: a clinical collaboration to evaluate drug combinations incorporating select clinical-stage oncology assets from BeOne with any of Revolution.

Business Wire • Aug 10, 2026

High Risk, High Reward: Inside The Revolution Medicines Bull Case

Revolution Medicines is evolving from a clinical-stage biotech to a near-term commercial oncology player, anchored by its RAS(ON) inhibitor platform. RVMD's robust $3.9 billion cash position and additional committed capital support aggressive pipeline expansion and commercial launch readiness, reducing near-term dilution risk. Daraxonrasib's potential FDA approval and commercial launch in pancreatic cancer could fundamentally transform RVMD's financial profile and validate its broader RAS-targeted strategy.

Seeking Alpha • Aug 7, 2026

Revolution Medicines Q2 Earnings Call Highlights

Revolution Medicines NASDAQ: RVMD said its second-quarter 2026 results reflected continued investment in late-stage cancer programs, commercial launch preparations and manufacturing capacity as it advances daraxonrasib and other RAS-targeted therapies across pancreatic and lung cancer.

MarketBeat • Aug 6, 2026

RVMD Posts Wider-Than-Anticipated Loss in Q2, Lifts '26 Expense View

Revolution Medicines posts a wider-than-expected loss in Q2 and raises its 2026 expense outlook again as investors weigh higher spending and pipeline progress.

Zacks Investment Research • Aug 6, 2026

Revolution Medicines, Inc. (RVMD) Q2 2026 Earnings Call Transcript

Revolution Medicines, Inc. (RVMD) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 5, 2026

Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

REDWOOD CITY, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial results for the quarter ended June 30, 2026, and provided an update on corporate progress.

GlobeNewsWire • Aug 5, 2026

Read Between These Lines As Eli Lilly, Hot IPO And More Face Key Test

As stocks like Eli Lilly, Twilio, Hinge Health and more move ahead of earnings report, pay attention to these chart lines.

Investors Business Daily • Aug 3, 2026

Revolution Medicines to Report Financial Results for Second Quarter 2026 After Market Close on August 5, 2026

REDWOOD CITY, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the second quarter of 2026 on Wednesday, August 5, 2026, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress.

GlobeNewsWire • Jul 29, 2026

FDA Accepts RVMD's Filing for Daraxonrasib in Pancreatic Cancer

Revolution Medicines' FDA filing for daraxonrasib in metastatic pancreatic cancer enters an accelerated review program, bringing its first commercial product closer.

Zacks Investment Research • Jul 23, 2026